Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 12Lymphoma, Non-Hodgkin 7Carcinoma, Non-Small-Cell Lung 5Lymphoma, Large B-Cell, Diffuse 4Breast Neoplasms 4Recurrence 3Melanoma 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Urinary Bladder Neoplasms 2Lymphoma, Follicular 2Cytokine Release Syndrome 2Craniopharyngioma 2Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Nasopharyngeal Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Temozolomide 100Radiotherapy 49Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 22Bevacizumab 22Lomustine 16Nivolumab 14Surgical Procedures, Operative 10atezolizumab 8Cyclophosphamide 8Biopsy 8abemaciclib 7Ipilimumab 7fludarabine 6Radiotherapy, Intensity-Modulated 6Carboplatin 6Aminolevulinic Acid 6olaparib 5Metformin 5Drug Therapy 5Diet, Ketogenic 5Dianhydrogalactitol 5poly ICLC 4cemiplimab 4Radiosurgery 4Photons 4Leukapheresis 4Immunoglobulin G 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × tocilizumab × 1 year × Clear all
NCT04729959 2026-04-01

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
59 enrolled
CNS

Astrocytoma, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡